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Abstract Depressive symptoms are common in schizo-
phrenia and they can occur during any phase of the
disorder. Early diagnosis, adequate differential diagnosis
and promptly initiated interventions have been shown to
reduce further deterioration of illness and to improve
patients’ quality of life. Common psychiatric rating scales
for early detection of depressive symptoms in schizophrenia
are Calgary Depression Scale for Schizophrenia and
Hamilton Depression Rating Scale, but the most appropri-
ate assessment instrument today regarding this topic is
Calgary Depression Scale for Schizophrenia. Treatment of
depression in schizophrenia consists of a combination of
pharmacologic and psychosocial approach. Atypical anti-
psychotics have advantages over typical in reducing
depressive symptoms in the context of schizophrenia. Most
of the studies referred that clozapine, olanzapine, quetiapine
and risperidone have an antidepressant spectrum of activity
in patients with schizophrenia. Antidepressant augmenta-
tion of antipsychotic treatment in schizophrenic patients
with depressive symptoms improves depressive symptom-
atology, particularly SSRI and SNRI augmentation.
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Depressive symptoms in schizophrenia
Depressive symptomatology has been recognized as a
feature of schizophrenia since Bleuler first introduced this
term in 1908. He described depressive symptoms as either
directly triggered by the very process of the disorder in the
acute stages (i.e. as essential symptoms of schizophrenia) or
as secondary symptoms of this disorder [1].
ICD-10 classification recognizes two diagnostic catego-
ries that encompass the coexistence of schizophrenia and
depression: post-schizophrenic depression (F20.4) and
schizoaffective disorder, depressed type (F25.1) [2]. In
1994, DSM classification defined a post-psychotic depres-
sion, which is called a post-psychotic depressive disorder of
schizophrenia in DSM-IV classification [2, 3]. This is,
however, a limited approach since there are other depres-
sive conditions associated with schizophrenia that have not
been covered by these diagnostic classifications [2].
Depressive symptoms in patients with schizophrenia
may be observed during each phase of the disorder: the
prodromal phase, the acute episode, the post-psychotic
phase and the chronic phase, over the long-term course.
Depressive symptoms are frequent in the prodromal
period but they are most commonly associated with the
acute phase of the disease. These symptoms most
frequently occur before the beginning of the treatment
and in as many as half of the patients with first psychotic
episode who have not started medication [4–6]. The close
relationship between depressive symptoms and acute
episodes supports the hypothesis that these symptoms are
an inherent characteristic of schizophrenia and suggests
that depressive symptoms and typical schizophrenic
symptoms may result from one and the same pathophys-
iological process [5, 7–10].
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In the course of the chronic phase of the disease, the
incidence of depressive symptoms is lower and ranges from
4 to 25% [11–15].
Post-psychotic depression, according to the current DSM
definition, is occurrence of symptoms during the residual
phase of depression i.e. it follows after the symptoms which
fulfill criterion A for schizophrenia have dissolved. Main
clinical signs of post-psychotic depression are depressive
affect and overall psychomotor retardation [3, 7, 16].
The majority of depressive symptoms that develop in
various phases of schizophrenia fail to fulfill the criteria for
major depressive episode of moderate or severe intensity.
Results from one study [17] showed that in the subjects
with schizophrenia the mild depression is predominant,
being present in over a half of the subjects (52%); 46% of
the subjects manifested moderate depression and 2% severe
depression. This means that patients with schizophrenia
more frequently develop depression of mild or moderate
intensity. The majority of researchers have come to the
same conclusion i.e. that mild and moderate depression are
the commonest degrees of depression intensity in patients
with schizophrenia, whereas severe depression is much less
frequently reported in these patients [1, 18–22].
Data from literature show significant diversity in
prevalence of depression in schizophrenic patients, ranging
from 7 to 75%, depending on the definition for depression.
In other words, depression may denote a description of
mood, syndrome (cognitive, affective and neurovegetative
symptoms) or a disorder (most commonly a major
depressive disorder). The wide range of prevalence of
depressive symptoms in schizophrenic patients is also due
to the fact that the studies have been performed in different
stages of the disease, that different methods have been
applied, as well as the differences in the treatment
conditions [21, 23–27]. Babinkostova and Stefanovski
[17] concluded that the incidence of patients with depres-
sive symptoms among the patients with schizophrenia was
54% i.e. out of 92 examined patients, 50 showed prominent
depressive symptoms, assessed objectively using the 17-
item Hamilton Rating Scale for Depression (score over 7).
Johnson [8] showed that 70% from the sample of 30
subjects with schizophrenia had depressive episode in two
years period and authors of another study [28] that were
assessing depression in 70 patients with first schizophrenic
episode (followed in 5 year period), concluded that 75% of
the patients had major depressive disorder at the beginning
of the schizophrenic episode. Depressive symptoms during
the acute phase of the disorder are registered even before
the start of the medication treatment and are present in
about 50% of the unmedicated patients, but the percentage
of the depressive symptoms in chronic schizophrenia
(clinically stabile patients) is lower [29]. In one study only
9% of the examined patients with schizophrenia, that were
clinically stabile and socially accepted, had depressive
symptoms [12].
Depression in schizophrenic patients has been shown to
be associated with family history of depression, early loss
of a parent, higher doses of depot antipsychotics, although
no significant difference between sexes has been demon-
strated [6, 16, 18, 30].
Subotnik and coworkers [31] have found that depression
in schizophrenia correlates with a positive family history
for depression indicating a genetic liability. Conversely,
other findings on a shared genetic liability between
depression and schizophrenia are questioning the concept
of genetic monocausality [32]. Many researchers report on
a strong genetic predisposition and accentuate that patients
with schizophrenia and depressive symptoms more fre-
quently have first-line relatives with unipolar depression [7,
19, 32, 33]. One study [17] demonstrated that in patients
with schizophrenia and depressive symptoms positive
history of depression is predominant (in 22%) and 20% of
them have a family history of schizophrenia.
Depressive symptoms play an important role in schizo-
phrenia as these contribute to a further worsening of already
existing deficit state and further exacerbation of illness. It is
important to define and clinically assess such symptoms
accurately as there is now increasing evidence that they can
be treated successfully [7, 18, 34, 35].
Depression in schizophrenia is associated with poor
overall outcome characterized by further deficits in psy-
chosocial functioning, increased rate of relapse, more
frequent and longer duration of hospitalizations, poor
response to pharmacological treatments, significant work
impairment, lower activity, dissatisfaction, less employment
and poorer quality of life. Cognitive impairment, poor
social functioning, substance abuse, negative attributional
style and suicide/suicide attempts have also been reported
[13, 16, 26, 32, 36]. This further contributes to the poor
prognosis of the illness. Early diagnosis, adequate differ-
ential diagnosis and promptly initiated interventions have
been shown to bring down the morbidity and mortality in
schizophrenic patients with depressive symptoms, to reduce
further deterioration of illness and to improve patients’
quality of life [7, 18, 32].
Instruments for early detection of depression
in schizophrenia
One of the most encouraging developments in schizophre-
nia management is the focused attention on aspects of the
early detection of depressive symptoms and the importance
of early interventions. Structured psychiatric clinical inter-
view is the first diagnostic procedure that should be
conducted for early detection of depressive symptoms in
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patients with schizophrenia. Common psychiatric rating
scales for clinical evaluation of presence and prominence of
depressive symptomatology in schizophrenia are Calgary
Depression Scale for Schizophrenia (CDSS) and Hamilton
Depression Rating Scale (HDRS). The most appropriate
dimensional assessment instrument today is Calgary
Depression Rating Scale for Schizophrenia, but Hamilton
Depression Rating Scale, from which some modified items
are also included in the CDSS, is still widely used in
clinical researches regarding this field. The Calgary
Depression Scale for Schizophrenia is a clinician-rated
depression scale specifically developed to assess the level
of depression in schizophrenia [37, 38]. It has been
extensively evaluated in both relapsed and remitted patients
and appears sensitive to change. The CDSS is a nine item
scale, each item scored from 0 to 3. This scale was derived
from the HDRS and the Present State Examination. Factor
analysis showed that the CDSS is unidimensional, has high
internal consistency, and significant strong correlation with
scores on the HDRS, Beck and BPRS depression scales.
The scale is currently available in 35 languages. Authors
of one study [9] compared the psychometric properties of
the Calgary Depression Rating Scale and the Hamilton
Depression Rating Scale for severity assessment of depres-
sion in schizophrenia. They investigated 119 inpatients with
acute schizophrenia using the CDSS, the HDRS and a
global 4-point Depression Severity Scale and they conclud-
ed that although both depression scales were correlated and
highly effective in separating mild, moderate and severe
depression, significant advantages emerged in favor of the
CDSS. Thus the CDSS should be used particularly for a
sensitive detection of mild (for example subthreshold)
depression at early stages or to assess schizophrenic
patients with severe depression who require through
follow-up assessment and specific interventions [9]. Also
Calgary Depression Scale for Schizophrenia seems to have
more efficiency and ability to distinguish between depres-
sion, negative and extrapyramidal symptoms [39]. Collins
et al. [40] demonstrated the methodological superiority
of the Calgary Depression Rating Scale in the assessment
of depressive symptoms in schizophrenia over scales
developed for nonschizophrenic populations such as the
Hamilton Depression Rating Scale and the Present State
Examination.
Depression may also occur as part of a prodromal
syndrome of schizophrenia. The interview for the
Retrospective Assessment of the Onset of Schizophrenia
is a semi-structured interview which can help determine
whether this is the case [41].
The Psychotic Depression Scale (PDS) also can be
useful for early detection of depression in schizophrenia
[41]. It has been shown that there is no overlap between
negative or extrapyramidal and depressive symptoms
assessed by the PDS in schizophrenic patients. The
Psychotic Depression Scale is a 32 item scale and each
item is rated from 0 to 7.
Some authors use the Beck Depression Inventory (BDI),
Montgomery-Asberg Depression Rating Scale and depres-
sion subscale of the Brief Psychiatric Rating Scale (BPRS)
for evaluation of severity of depressive symptoms in
schizophrenic patients [27, 42–44].
Kim et al. [45] assessed the following four depression
scales for their diagnostic validity as measures of
depressive disorder in schizophrenia: the Calgary De-
pression Scale for Schizophrenia (CDSS), the Beck
Depression Inventory (BDI), the Hamilton Rating Scale
for Depression (HAM-D), and the depression subscale
of the PANSS (PANSS-D). Their results suggested that
the CDSS may provide the best assessment for
depression in patients with schizophrenia. Hausmann
and Fleischhacer [46] also recommend the Calgary
Depression Scale in schizophrenic patients with depres-
sive symptoms and also Hillside Akathisia Scale to help
establish the right diagnosis.
The Positive and Negative Syndrome Scale (PANSS), the
Simpson-Angus Rating Scale (SARS), Barnes Akathisia
Scale, Abnormal Involuntary Movement Scale (AIMS) and
the Rating Scale for Extrapyramidal symptoms (ESRS) are
used to differentiate depression from the negative and
extrapyramidal symptom-related depressive phenomena in
schizophrenia [1, 43, 45].
Differential diagnosis of depression in schizophrenia
There are a number of important differential diagnoses of
depressive symptoms in schizophrenia. A major challenge
in the clinical assessment of schizophrenia is the differen-
tiation among depressive features, negative symptoms and
neuroleptic side effects [47]. Differential diagnoses to
consider also include schizoaffective disorder and organic
conditions [16]. Depression may also be an understandable
psychological reaction to schizophrenia. When all of these
possibilities have been excluded, there is evidence that
depression is perhaps most often an integral part of the
schizophrenic process itself [5, 7, 8]. It is essential to
differentiate between depressive symptoms and previous
mentioned conditions and to manage them accordingly, in
order to reduce the risk of further morbidity and mortality
[18, 29].
A key issue in the differential diagnosis of depressive
symptoms in patients with schizophrenia is disentangling
the contribution of negative symptoms. Based on DSM-IV
classification, negative symptoms of schizophrenia include
affective flattening, alogia, avolition and anhedonia [41].
There is thus a great overlap between symptoms of
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depression and negative symptoms of schizophrenia [48].
Diminished interest, pleasure, energy, or motivation along
with psychomotor retardation and impaired ability to
concentrate are relevant overlapping features. Prominent
subjectively low mood, suggesting depression, and prom-
inent blunting of affect, suggesting negative symptoms, are
the two features which are most helpful in differentiating
the two syndromes. Other symptoms that help to establish
the diagnosis of depression include some of the main
psychological features that occur in primary depressive
illness, such as hopelessness, helplessness, worthlessness,
guilt, anxiety and suicidal thinking. In schizophrenia, the
biological features of the depressive syndrome, such as
insomnia and retardation, are not always present—and if
they are present, they can be more difficult to disentangle
from negative symptoms and can be an intrinsic part of the
illness separate from any superimposed depressive syn-
drome [7, 16, 32, 49].
Schizoaffective disorder has to be differentiated from
schizophrenia. In DSM-IV schizoaffective disorder refers to
patients in whom a full affective syndrome coincides with
the florid psychotic syndrome but who also have substantial
periods of psychosis in the absence of an affective
syndrome [16, 32, 41].
Dopamine blockade by a neuroleptic drug could theo-
retically lead to anhedonia and perhaps, depression. Indeed,
a state of dysphoria is commonly described by neuroleptic-
treated patients.
Neuroleptic-induced akinesia is extrapyramidal side
effect of neuroleptic treatment involving impaired ability
to initiate and sustain motor behavior. Patients with this
form of akinesia may or may not have the classical
parkinsonian feature of decreased accessory motor move-
ments. They act “as if their starter motor is broken,” and
they consequently appear to lack spontaneity. Akinesia may
even protect against suicidal behavior, but not against
suicidal thinking [16, 32].
Akathisia is another extrapyramidal side effect of
neuroleptic treatment that can easily be confounded with
depression. Patients with akathisia behave “as if their starter
motor won’t stop” and often experience this state as
substantially dysphoric. Akathisia has been associated with
both suicidal ideation and, perhaps as a consequence of a
general tendency toward motor action, suicidal behavior
[16, 32].
A number of medical/organic factors can present as
depression in patients with schizophrenia. These include
cardiovascular disorders, pulmonary infections, autoim-
mune diseases, anemia, cancer, metabolic, neurological
and endocrine disorders. Various pharmaceuticals used in
medical treatment such as β blockers, other antihyperten-
sive agents, sedative hypnotics, antineoplastics, barbitu-
rates, nonsteroidal anti-inflammatory drugs, sulfonamides,
and indomethacin can cause depression as a side effect.
Depression can also accompany the discontinuation of
other prescribed medications such as corticosteroids and
psychostimulants. Used or abused substances such as
alcohol, cannabis, cocaine, or narcotics can contribute to
depression either on the basis of acute use, chronic use, or
discontinuation [16, 32].
Reactions to disappointments, a sense of loss or
powerlessness, or awareness of psychotic symptoms or
psychological deficits can certainly present as or contribute
to depression, especially when depression follows closely
after a stressful event or exacerbation of schizophrenia.
Such reactions can be acute and chronic. An acute reaction
to disappointment or stress is suggested by the parallel
history of a recent compatible event. Chronic reactions to
disappointment or stress have also been termed the
demoralization syndrome. Differentiating such a syndrome
from depression is not always easy. It is characterized by
hopelessness and helplessness, with a lack of confidence
and feelings of incompetence. Adjunctive psychotherapy, e.g.
psychoeducational family therapy or cognitive behavioral
therapy is the mainstay of helping patients to cope with
demoralization syndromes [7, 16, 32].
In earlier times, the term postpsychotic depression was
used to describe a dysphoric state that immediately
followed a psychotic episode. DSM-IV now suggests that
the term “postpsychotic depression” be used to describe
depression that occurs at any time after a psychotic episode
in schizophrenia, even after a prolonged interval [16, 32].
The appearance of a depression-like state as a prodrome
of a new psychotic episode is a short-lived phenomenon,
often lasting only a couple days to a couple weeks, before
being superseded by more prominent and definitive
psychotic symptoms [16, 32].
Treatment of depression in schizophrenia
The assessment and treatment of depressive symptoms in
schizophrenia remains clinically challenging. The therapeu-
tic goal is significantly to reduce the excess morbidity and
mortality associated with depressive symptoms and to
improve individual patients’ quality of life [27]. A rational
approach to treating depression in schizophrenia flows from
considering the differential diagnosis [16]. The first steps
are to exclude cases of schizoaffective disorder and to treat
them appropriately, to treat any medical conditions that are
present and to consider the possibility of substance misuse
as a contributing factor. Any evidence that antipsychotic
medication is producing akinesia should lead to a reduction
in dosage and/or the introduction of anticholinergic medi-
cation. Akathisia, with its concomitant feeling of dysphoria,
should always be considered in patients describing subjec-
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tive mood disturbance. The akathisia/dysphoria syndrome,
if present, requires active management. Use of an anticho-
linergic drug is generally effective. Other options include
β-adrenoceptor antagonists (e.g. propranolol), a benzodia-
zapine or a change in antipsychotic drug. If the above
factors have been addressed and the clinician is sure that
negative symptoms are not being mistaken for depressive
symptoms, then the treatment options are largely dictated
by the stage of the illness. During acute episodes,
depressive symptoms should not be treated separately from
other symptoms and are likely to resolve as the episode
resolves. In the majority of cases increased antipsychotic
medication, increased psychosocial support and, if neces-
sary, hospitalization, will successfully treat depression as
well as positive symptoms. Moller HJ [50] in his
comprehensive review reported that besides the potential
risk of inducing depressive symptoms, the first generation
antipsychotics seem to have a certain antidepressive effect,
in the sense that depressive symptoms secondary to positive
symptoms can be alleviated with the reduction of positive
symptoms. The second generation antipsychotics seem to
have no risk to induce depressive symptoms, appear to have
better antidepressive effect and therefore represent a better
option for the treatment of depressive symptoms in
schizophrenic patients. There is accumulating evidence that
the new atypical antipsychotics are more efficacious in
treating the depression associated with an acute episode
[51]. Olanzapine, for example, is superior to haloperidol in
this regard [42, 52, 53]. Other atypicals, such as risper-
idone, ziprasidone and zotepine, may also have a mood-
elevating effect. The atypicals may prove to be useful for
the depression that emerges during the chronic phase of the
illness. Clozapine has been shown to reduce hopelessness,
depression and suicidality in patients with chronic schizo-
phrenia [54–59]. Clinicians should consider switching
patients to an atypical antipsychotic if they are not taking
one already [16]. In addition, dose optimization needs to be
targeted towards depressive as well as positive and negative
psychotic symptoms [16, 41, 60]. Administration of
antidepressants in combination with antipsychotics seems
to be a meaningful option to treat depressive symptoms in
schizophrenia. Data collected show that treatment with
antidepressants in addition to antipsychotic treatment is
only of limited benefit [25, 61]. This might especially be
the case in combining antidepressants with second gener-
ation antipsychotics. The risk of inducing positive symp-
toms by antidepressants has to be considered [50]. Despite
this there is a good case for the prescription of an
antidepressant when the patient has persistent depressive
symptoms and is not in a phase of acute illness [60]. Recent
studies have shown that antidepressants are prescribed by
clinicians to 30% of inpatients and 43% of outpatients of all
ages with schizophrenia and depressive symptoms [62].
SSRIs when compared with the triciclics appear to be the
treatment of choice considering the side effects and efficacy
[16, 18]. One needs to start with a low dose and then
cautiously titrate upward to reduce depressive symptoms.
If remission is not achieved after adequate treatment
duration (8–12 weeks) or with an adequate dose (similar
to that used for major depression without schizophrenia),
switching to another agent or adding augmenting therapy
is recommended.
Whitehead and coworkers [63] in their systematic review
of antidepressants for the treatment of depression in patients
with schizophrenia concluded that the meta-analysis of the
5 suitable trials found that using antidepressants was
beneficial and there was no evidence that antidepressant
treatment led to a deterioration on psychotic symptoms in
the trials. On the other hand, Zisook et al. [24] in their
research paper compared the patients who were taking
antidepressant medications to those who were not, on the
17-item Hamilton depression scale total score and on the
percentage of subjects classified as minimally, mildly and
moderately to severely depressed and they found no
difference between groups on any of these measures.
Also they stated that correlation between severity of
depression and daily neuroleptic dose was low, negative
and nonsignificant.
Siris [64] reported that long-term maintenance treatment
with antidepressants would be beneficial for patients who
responded favorably to the initial treatment. He stated that
besides the fact that some patients were resistant and even
refractory to pharmacological treatment, it would be also
probable that therapists found it difficult to administer high
doses of antidepressants to these patients, because of the
fear of recidivation of psychotic symptoms which lead to
the use of subtherapeutical doses of antidepressants making
it difficult to cute this syndrome and to a subsequent
chronification of the condition.
Table 1 presents the main results from the conducted
studies for antidepressant augmentation in schizophrenic
patients with depressive symptoms. Results from the
several studies showed that citalopram augmentation of
antipsychotic treatment in patients with schizophrenia and
depressive symptoms improves depressive symptomatology
[65–67]. Authors of several studies evaluated addition of
venlafaxine to antipsychotic treatment in schizophrenic
patients with depression and they concluded that the dual
mechanism of this drug may contribute to a more complete
antidepressant response than the single mechanism of
selective serotonin reuptake inhibitor medication [68, 69].
Psychosocial therapies in combination with pharmaco-
therapy are very important additional treatments needed for
this patient population in order to alleviate residual
symptoms and to improve social functioning and quality
of life [16, 41]. Cognitive therapy also has been shown to
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be effective, although its role in the treatment of depressive
symptoms in particular has not been studied [7, 35, 41, 70].
Antipsychotics and depression in schizophrenia
Several different concepts have been employed to explain
the role of antipsychotics in schizophrenic patients with
depression. It has been suggested that antipsychotics cause
a so called “pharmacogenic depression” by a direct action
on the dopaminergic system affecting the pleasure and
reward pathways [32, 71, 72]. Akinesia and other extrapy-
ramidal adverse effects of antipsychotics, excluding tremor,
accompanied by depressed mood or dysphoria may also
mask depression. The so called “akinetic depression”
accounts for 10–15% of depressive symptoms and it
includes a reduced level of activity as well as anhedonia,
responding to anticholinergic medication. Certain authors
suggest that iatrogenic depression associated with the
extrapyramidal adverse reactions of the antipsychotic
treatment is less common nowadays than it used to be in
the past [18, 73, 74].
Although certain observations support the hypothesis
of a “pharmacogenic depression”, suggesting that anti-
psychotics are responsible for several cases of depression
in schizophrenia, the evidence against it carries more
weight [75, 76]. Depression may also occur in patients
with schizophrenia who do not receive antipsychotics, and
when antipsychotics are discontinued, the proportion of
patients who need antidepressants is increased. Several
studies have demonstrated that there are no differences
between depressed and non-depressed patients with
schizophrenia in terms of the dose of the antipsychotic
that they received [7, 24, 27].
There are several reasons to suspect that schizophrenia
treated with atypical antipsychotics may prove to be a
different condition than schizophrenia treated with conven-
tional neuroleptics from the point of view of depression.
Atypical antipsychotic agents have a greatly reduced
extrapyramidal side effect profile. Since akinesia and akathisia
figure prominently in the differential diagnosis of depression
in schizophrenia, this issue could be responsible for a different
expression of depression in schizophrenia. Since atypical
agents seem to rely much less exclusively on dopaminergic
blockade for their therapeutic activity, they might circumvent
the mechanism of neuroleptic-induced dysphoria that could
contribute to the depression syndrome. Atypical antipsy-
chotics have frequently been reported to be superior to
standard neuroleptics in the treatment of negative symptoms,
which can sometimes appear similar to depression and it is
possible that atypical antipsychotic agents have direct
antidepressant activity on their own. Combinations of any or
all of these effects could potentially be responsible for
more favorable depression profiles in patients treated
with atypical antipsychotics versus conventional neuro-
leptics [16, 23, 28, 48].
The broad array of affinities for receptor sites attributable
to the novel atypical antipsychotic agents (including a wide
array of 5-hydroxytryptamine [5-HT], dopamine [other than
D2], and muscarinic sites as well as α1-noradrenergic and
histamine-1 receptor sites) suggest a variety of potential
mechanisms through which atypical antipsychotics might
exercise antidepressant effects and that their antipsychotic
and antidepressive effects are mostly based on different
pharmacological mechanisms [16, 77].
The dopamine deficit in cortical prefrontal areas was a
unifying hypothesis to explain both some symptoms of
depression and negative symptoms of schizophrenia.
Table 1 Antidepressant augmentation in schizophrenia with depressive symptoms
Study Year Study design Type of antidepressant Main results
Kasckow et al. 2010 Randomized, placebo-controlled Citalopram Improvement in depressive symptoms,
negative symptoms, social functioning
and quality of life with citalopram
Zisook et al. 2009 Double-blind, randomized,
placebo-controlled
Citalopram Significantly more effective than placebo
in improving depressive symptoms
Ciobanu et al. 2008 Randomized, prospective Venlafaxin, fluvoxamine, mirtazapine Improvement in depressive symptoms
with all antidepressants, quicker
response with venlafaxine
Mazeh et al. 2004 Open-label study Venlafaxine Improvement in depressive symptoms
Addington et al. 2002 Randomized, double-blind,
prospective,
placebo-controlled
Sertraline Limited benefit of added sertraline
Kasckow et al. 2001 Open-label study Citalopram Significant improvement in HAMD scores
Mullholand et al. 1997 Double-blind, placebo-controlled Sertraline No significant benefit of added sertraline
(limited benefit)
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Studies in animal confirm this view and show that the
association of an atypical antipsychotic drug and an SSRI
(olanzapine plus fluoxetine) increases synergistically the
release of dopamine in prefrontal areas [48].
Harrow and coworkers [74] observed that depression in
schizophrenia correlated with first generation antipsychotic
treatment and suggested that depression is associated with
anhedonia and mesolimbic dopaminergic dysfunction,
which may be potentiated by dopaminergic blockade
induced by typical antipsychotics. Although depressive
symptoms are described in neuroleptic-naive schizophrenic
patients having a first episode, patients receiving conven-
tional antipsychotic drugs may have higher rates [41, 42].
By contrast second-generation antipsychotics may have
some efficacy for depressive symptoms over improvement
in positive and negative symptoms, perhaps due to their
direct antidepressant effects [55, 77]. On the other hand, as
reported by Freudenreich et al. [23] there was no difference
in depressive symptoms between the different classes of
antipsychotics used (typical, atypical antipsychotics and a
clozapine group). Also this study found that HAMD scores
did not vary between the group receiving antidepressant
therapy (22% of the examinees) and the rest of the sample,
nor did PANSS scores. Authors of this study stated that
treatment with second-generation antipsychotics did not
confer benefit compared to first-generation antipsychotics
with regard to depressive symptoms. Also they concluded
that mood stabilizers were associated with less depression.
Similar to this, Mauri and coworkers [27] in their article
refer to comparison of first and second generation anti-
psychotics did not found that atypical antipsychotics as a
class are more effective on the depression dimension during
the course of schizophrenia than typical ones. Their results
showed that none of the drugs seemed to have a real
depressogenic effect. They did not confirm correlation
between the severity of the depressive symptoms and the
doses of the antipsychotics. They referred that all of the
typical and atypical antipsychotics alone improved depressive
symptoms, but the improvement was statistically significant in
cases of fluphenazine decanoate, haloperidol, olanzapine,
risperidone and l-sulpiride, which partially conflicts with
some published data concerning the depressogenic effect of
classical neuroleptics (“pharmacogenic depression”), espe-
cially fluphenazine decanoate and haloperidol.
Aguilar et al. [54] in their article stated that second-
generation antipsychotic agents appear to have a better
potential for preventing suicide in schizophrenia. The
strongest and perhaps unique evidence has been shown
for clozapine, which seems to have a clinically relevant
advantage over both first- and second-generation antipsy-
chotics for reducing suicidality. Suggestion that suicidality
may be reduced in schizophrenic patients receiving cloza-
pine is also confirmed by other authors [55–59].
Table 2 presents the main results from the studies that
evaluated effects of the different types of antipsychotics on
depression in schizophrenic patients. The strongest evi-
dence for the benefit of atypical antipsychotics in the
treatment of concurrent depressive symptoms in schizo-
phrenic patients comes from trials of olanzapine and
ziprasidone. First randomized double-blind study regarding
efficacy and tolerability of atypical antipsychotics in the
treatment of patients with schizophrenia and depressive
symptoms, compared olanzapine with ziprasidone therapy
in these patients. Their results showed that for up to
8 weeks patients treated with olanzapine or ziprasidone had
significant improvements on Calgary Depression Scale for
Schizophrenia, but treatment group differences were not
statistically significant. Over 24 weeks, olanzapine treated
patients showed significantly greater improvements in
depressive symptoms and GAF scores [43]. In a compar-
ison of olanzapine and ziprasidone for the 6-week treatment
of patients with acute schizophrenia or schizoaffective
disorder, both antipsychotics were efficacious in improving
positive, negative and depressive symptoms without signif-
icant treatment differences, suggesting that ziprasidone was
as efficacious as olanzapine in improving the Calgary
Depression Scale for Schizophrenia score [78]. Another
study that compared olanzapine and ziprasidone in patients
with schizophrenia demonstrated significantly greater
improvement in olanzapine-treated patients on positive,
negative and depressive symptoms at the 28-week study,
suggesting that treatment response may differentiate over
longer treatment durations [79]. In a systematic review and
meta-analysis, Leucht et al. [80] reported that olanzapine
was found to have superior efficacy compared to aripipra-
zole, quetiapine, risperidone and ziprasidone. In addition,
clozapine had superior efficacy compared to zotepine and
risperidone when clozapine doses at 400 mg a day were
used.
Tollefson et al. [42] in their double-blind, controlled
clinical trial compared the use of olanzapine with that of
haloperidol for up to 52 weeks of treatment in patients with
schizophrenia, schizoaffective and schizophreniform disor-
der and they referred that the use of olanzapine was
statistically significant superior to that of haloperidol in
the early improvement of depressive signs and symptoms
evaluated with the Montgomery-Asberg Depression Rating
Scale and there was no dose difference based on the
depressive signs and symptoms. Similar results presented
other studies that evaluated the efficacy of olanzapine
compared to risperidone and haloperidol in the treatment of
schizophrenia-related depressive symptoms [52, 53].
Most studies referred that olanzapine, risperidone or
ziprasidone may have an antidepressant spectrum of
activity in patients with schizophrenia [16, 43, 56, 78–80].
One trial [44] presented data suggesting that risperidone
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may be inferior to haloperidol in terms of BPRS anxiety/
depression factor improvement. One research study [53]
suggested that olanzapine was superior to risperidone in
alleviating depression.
It is noteworthy that quetiapine has been found to have an
antidepressant effect. In one study patients suffering from
schizophrenia derived greater reduction in depressive scores in
comparison to haloperidol [81]. In another study quetiapine
was found to improve symptoms of depression, over the
course of long term use [82]. Contrary to this the authors of
one case report [47] presented a quetiapine-associated
depression in schizophrenic patients. It is the first description
of depression associated with quetiapine treatment and their
authors suggested that atypical antipsychotics may be a cause
of depression, but further data based on controlled studies are
required before one can draw definitive conclusions.
In a recent review by Furtado et al. [83] the authors
included randomized clinical trials of atypical antipsychotic
drugs used for the treatment of patients with a diagnosis of
both schizophrenia and depression. One trial found no
significant differences between quetiapine and haloperidol
for the outcome of less than 50% reduction in PANSS score
[81]. In a second trial, sulpiride was compared to
chlorpromazine; the group treated with sulpiride had more
reductions in depressive symptoms based on scores of the
Comprehensive Psychopathologic Rating Scale [84]. In a
third trial, Jasovic [58] used Hamilton Depression Rating
Scale scores to compare clozapine to any other antipsy-
chotic plus an antidepressant; use of clozapine lead to
greater reductions in Hamilton symptoms.
Authors of this review article conducted a cross-sectional
study which involved 92 patients with schizophrenic
disorder, 50 of whom with prominent depressive symptoms
(total score >7 on the 17-item Hamilton Rating Scale for
Depression) with the aim of evaluation of the effect of the
different type of antipsychotic treatment administered on
the depression intensity in schizophrenic patients. The
group was created by randomization of inpatients and
outpatients of both sex who were treated at the University
Clinic of Psychiatry within a period of 6 months. For the
purposes of the study, the test group was subsequently
subdivided in several subgroups according to the type of
used antipsychotic therapy (oral/depot; typical/atypical;
olanzapine/risperidone/clozapine). 60% of the examinees
were taking oral antipsychotics and 40% of them were
administered depot antipsychotic treatment (long-acting
atypical antipsychotic).
According to the treatment with different classes of oral
antipsychotics (typical/atypical), the results indicated that
20% of the oral antipsychotic group were taking typical
antipsychotics (haloperidol), whereas 80% of these subjects
received atypical oral antipsychotic medications. From the
atypical oral antipsychotic subgroup 37.5% were taking
olanzapine, same percentage were on risperidone and 25%
were on clozapine.
The results obtained from this study suggested that
subjects who received depot antipsychotics had less severe
depression in comparison to the subjects who received oral
antipsychotics, although this difference, when tested using
the t-test for independent samples, was not statistically
Table 2 Effects of antipsychotics on depression in schizophrenia
Study Year Study design Type of antipsychotic medication Main results
Kinon et al. 2006 Randomized, double-blind Olanzapine vs. ziprasidone Olanzapine showed significantly greater
improvement in depressive symptoms
Breier et al. 2005 Randomized, controlled, double-blind Olanzapine vs. ziprasidone Significatntly greater improvement in
olanzapine-treated patients on depressive,
positive and negative symptoms
Mergui et al. 2005 Case study Quetiapine Quetiapine-associated depression in
schizophrenic patients
Simpson et al. 2004 Randomized, controlled, double-blind Ziprasidone vs. olanzapine Both antipsychotics were efficacious in
improving depressive, positive and
negative symptoms
Emsly et al. 2003 Randomized, controlled Quetiapine vs. haloperidol Quetiapine showed greater reduction in
depressive scores
Tollefson et al. 1999 Double-blind, randomized Olanzapine vs. risperidone Olanzapine was superior to risperidone
in alleviating depression
Tollefson et al. 1998 Randomized, controlled, double-blind Olanzapine vs. haloperidol Olanzapine was associated with a
significantly higher improvement
of depressive symptoms
Ceskova et al. 1993 Double-blind, randomized Risperidone vs. haloperidol Risperidone was inferior to haloperidol
in terms of BPRS depression factor
improvement
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significant. Contrary to this, some earlier studies in this
direction showed a positive relationship between the intensity
of depression and a higher dose of depot antipsychotics in
patients with schizophrenia [6, 7, 18, 30].
Further results of this study showed that subjects treated
with depot antipsychotics had statistically significant lower
depression intensity in comparison to the subjects treated
with typical oral antipsychotics.
Figure 1 presents the difference in depression intensity
between the subgroup with typical oral antipsychotics and
the subgroup with atypical oral antipsychotics.
The tested difference in depression intensity between the
subgroups treated with different types of oral atypical
antipsychotics in this study showed that the subjects treated
with clozapine had statistically significant lower depression
intensity in comparison to the subjects treated with
risperidone (Fig. 2) and also they had lower depression
intensity in comparison to the subjects treated with
olanzapine, but statistically not significant. The patients
treated with olanzapine had lower depression intensity in
comparison to those treated with risperidone, but statisti-
cally not significant.
Conclusions and outlook
Depressive symptoms are common in patients with schizo-
phrenia and they can occur during any phase of the
disorder. They are associated with a variety of undesirable
outcomes and are a significant cause of higher rates of
morbidity and mortality in these patients. Early diagnosis,
adequate differential diagnosis and promptly initiated
interventions have been shown to bring down the morbidity
and mortality in schizophrenic patients with depressive
symptoms, to reduce further deterioration of illness and to
improve patients’ quality of life. Structured psychiatric
clinical interview is the first diagnostic procedure that
should be conducted for early detection of depressive
symptoms in patients with schizophrenia. Common psychi-
atric rating scales for clinical evaluation of presence and
prominence of depressive symptomatology in schizophre-
nia are Calgary Depression Scale for Schizophrenia (CDSS)
and Hamilton Depression Rating Scale (HDRS). The most
appropriate dimensional assessment instrument today is
Calgary Depression Rating Scale for Schizophrenia, but
Hamilton Depression Rating Scale, from which some
modified items are also included in the CDSS, is still
widely used in clinical researches regarding this field. The
Calgary Depression Scale for Schizophrenia is a clinician-
rated depression scale specifically developed to assess the
level of depression in schizophrenia. The CDSS showed
higher sensitivity in detecting mild and severe depression.
The results can help clinicians to initiate psychosocial
interventions and medications. The Psychotic Depression
Scale (PDS) also can be useful for early detection of
depression in schizophrenia. It has been shown that there is
no overlap between negative or extrapyramidal and
depressive symptoms assessed by the PDS in schizophrenic
patients. The Positive and Negative Syndrome Scale
(PANSS), the Simpson-Angus Rating Scale (SARS), Barnes
Akathisia Scale, Abnormal Involuntary Movement Scale
(AIMS) and the Rating Scale for Extrapyramidal symptoms
(ESRS) are used to differentiate depression from the
negative and extrapyramidal symptom-related depressive
phenomena in schizophrenia.
An appropriate treatment approach to depression in
schizophrenia begins with a consideration of the differential
diagnostic possibilities. Depressive symptoms should be
adequately differentiated from negative symptoms, schizo-
affective disorder, neuroleptic induced side effects, reac-
tions to disappointments and a number of medical/organic
factors. Treatment of depressive symptoms in schizophrenia
is accomplished through a combination of pharmacologic
and psychosocial approach. Atypical antipsychotics have
advantages over typical in reducing depressive symptoms
in the context of schizophrenia. They do not induce
depressive symptoms, which is known side effect ofFig. 2 Total score on HAMD - risperidone/clozapine
Fig. 1 Total score on HAMD - typical vs. atypical oral antipsychotics
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traditional neuroleptics. Their antidepressive potential is
presumably related to their pharmacological mechanisms,
which differ from those of traditional neuroleptics. The
benefits of atypical antipsychotics might be of relevance
also for reducing the risk of suicidality. From a pharmaco-
logic perspective, the treatment of depressive symptoms in
patients with schizophrenia requires antipsychotics and
antidepressants. A lot of studies referred that clozapine,
olanzapine, quetiapine and risperidone have an antidepres-
sant spectrum of activity in patients with schizophrenia.
Clozapine has been shown to reduce suicidality in
schizophrenic patients with depression. Most of the
studies showed that antidepressant augmentation of
antipsychotic treatment in patients with schizophrenia
and depressive symptoms improves depressive symp-
tomatology, especially SSRI and SNRI augmentation.
Implementing psychosocial interventions in combination
with pharmacotherapy is also an important part of
patients’ treatment plan.
We can conclude that in patients with schizophrenia
early detection of depressive symptoms can be obtain
conducting structured psychiatric clinical interview and
using the appropriate assessment instruments regarding this
topic in everyday psychiatric clinical practice. In schizo-
phrenic patients with depressive symptoms preferable
pharmacological treatment include use of atypical antipsy-
chotics and antidepressants augmentation, particularly SSRI
and SNRI. Pharmacological treatment in these patients
should be combined with psychosocial interventions. Early
diagnosis and promptly initiated interventions have been
shown to reduce further deterioration of illness and to
improve patients’ quality of life.
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